CytomX Therapeutics Inc (CTMX) Shares Bought by Perceptive Advisors LLC

Share on StockTwits

Perceptive Advisors LLC grew its stake in CytomX Therapeutics Inc (NASDAQ:CTMX) by 9.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,911,715 shares of the biotechnology company’s stock after purchasing an additional 250,000 shares during the quarter. CytomX Therapeutics makes up approximately 1.7% of Perceptive Advisors LLC’s investment portfolio, making the stock its 17th largest position. Perceptive Advisors LLC owned 0.06% of CytomX Therapeutics worth $43,588,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Legal & General Group Plc boosted its position in CytomX Therapeutics by 15.3% during the third quarter. Legal & General Group Plc now owns 7,036 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 934 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in CytomX Therapeutics by 8.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 20,415 shares of the biotechnology company’s stock worth $308,000 after acquiring an additional 1,565 shares during the last quarter. Wedbush Securities Inc. boosted its position in CytomX Therapeutics by 8.1% during the fourth quarter. Wedbush Securities Inc. now owns 25,355 shares of the biotechnology company’s stock worth $383,000 after acquiring an additional 1,900 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in CytomX Therapeutics by 18.5% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 15,904 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 2,478 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in CytomX Therapeutics by 6.5% during the fourth quarter. Bank of America Corp DE now owns 55,574 shares of the biotechnology company’s stock worth $839,000 after acquiring an additional 3,416 shares during the last quarter. Hedge funds and other institutional investors own 83.82% of the company’s stock.

NASDAQ:CTMX opened at $10.75 on Tuesday. The stock has a market capitalization of $480.89 million, a price-to-earnings ratio of -5.30 and a beta of 0.70. CytomX Therapeutics Inc has a 1-year low of $9.38 and a 1-year high of $34.98.

A number of research firms recently weighed in on CTMX. BidaskClub upgraded shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 11th. Wedbush lowered their price target on shares of CytomX Therapeutics from $35.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 27th. Barclays began coverage on shares of CytomX Therapeutics in a research report on Monday, March 11th. They set an “overweight” rating and a $16.00 price target on the stock. Goldman Sachs Group upgraded shares of CytomX Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, December 13th. Finally, Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, January 8th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.03.

In other news, General Counsel Lloyd A. Rowland bought 9,000 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were bought at an average cost of $10.33 per share, for a total transaction of $92,970.00. Following the acquisition, the general counsel now directly owns 9,979 shares of the company’s stock, valued at approximately $103,083.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics Inc (CTMX) Shares Bought by Perceptive Advisors LLC” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://weekherald.com/2019/03/19/cytomx-therapeutics-inc-ctmx-shares-bought-by-perceptive-advisors-llc.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: How Do You Make Money With Penny Stocks?

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.